Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. Kato K, et al. Among authors: shirakawa y. Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. Esophagus. 2023. PMID: 36401133 Free PMC article. Clinical Trial.
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Daiko H, Marafioti T, Fujiwara T, Shirakawa Y, Nakatsura T, Kato K, Puccio I, Hikichi T, Yoshimura S, Nakagawa T, Furukawa M, Stoeber K, Nagira M, Ide N, Kojima T. Daiko H, et al. Among authors: shirakawa y. Cancer Immunol Immunother. 2020 Nov;69(11):2247-2257. doi: 10.1007/s00262-020-02619-3. Epub 2020 Jun 4. Cancer Immunol Immunother. 2020. PMID: 32500232 Free PMC article. Clinical Trial.
Long-term outcomes of endoscopic versus surgical resection for MM-SM1 esophageal squamous cell carcinoma using propensity score analysis.
Yamauchi K, Iwamuro M, Nakagawa M, Takenaka R, Matsueda K, Inaba T, Yoshioka M, Toyokawa T, Tanaka S, Kanzaki H, Kawano S, Kawahara Y, Shirakawa Y, Okada H; Okayama Gut Study Group. Yamauchi K, et al. Among authors: shirakawa y. Esophagus. 2021 Jan;18(1):72-80. doi: 10.1007/s10388-020-00775-0. Epub 2020 Sep 2. Esophagus. 2021. PMID: 32876825
Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study.
Mine S, Kurokawa Y, Takeuchi H, Terashima M, Yasuda T, Yoshida K, Yabusaki H, Shirakawa Y, Fujitani K, Sano T, Doki Y, Kitagawa Y. Mine S, et al. Among authors: shirakawa y. Gastric Cancer. 2022 Mar;25(2):430-437. doi: 10.1007/s10120-021-01255-9. Epub 2021 Sep 30. Gastric Cancer. 2022. PMID: 34590178
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N, Noma K, Kunitomo T, Hashimoto M, Maeda N, Tanabe S, Sakurama K, Shirakawa Y, Fujiwara T. Nishiwaki N, et al. Among authors: shirakawa y. Esophagus. 2022 Oct;19(4):626-638. doi: 10.1007/s10388-022-00934-5. Epub 2022 Jul 6. Esophagus. 2022. PMID: 35792947
MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus.
Okumura T, Fujii T, Terabayashi K, Kojima T, Takeda S, Kashiwada T, Toriyama K, Hijioka S, Miyazaki T, Yamamoto M, Tanabe S, Shirakawa Y, Furukawa M, Honma Y, Hoshino I, Nabeya Y, Yamaguchi H, Uemoto S, Shimada Y, Matsubara H, Ozawa S, Makuuchi H, Imamura M. Okumura T, et al. Among authors: shirakawa y. Oncol Lett. 2023 May 12;26(1):276. doi: 10.3892/ol.2023.13862. eCollection 2023 Jul. Oncol Lett. 2023. PMID: 37274462 Free PMC article.
421 results